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Mammary Gland In Vivo
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Department of Cancer Biology (MC.C., C.W., Z.L., G.D.S., N.E.W., S.A., L.C., Y.L., R.G.P), Kimmel
Cancer Center (M.C.C., C.W., Z.L., G.D.S., N.E.W., S.A., L.C., Y.L., M.P.L., R.G.P.), and Department of
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The CCND1 gene, which is frequently overexpressed in cancers, encodes the regulatory subunit of
a holoenzyme that phosphorylates the retinoblastoma protein. Although it is known that cyclin
D1 regulates estrogen receptor (ER) transactivation using heterologous reporter systems, the in
vivo biological significance of cyclin D1 to estrogen-dependent signaling, and the molecular
mechanisms by which cyclin D1 is involved, are yet to be elucidated. Herein, genome-wide expres-
sion profiling conducted of 17-estradiol-treated castrated virgin mice deleted of the Ccnd1 gene
demonstrated that cyclin D1 determines estrogen-dependent gene expression for 88% of estro-
gen-responsive genes in vivo. In addition, expression profiling of 17-estradiol-stimulated cyclin
D1 small interfering RNA treated MCF7 cells shows cyclin D1 is required for estrogen-mediated
gene expression in vitro. Genome-wide chromatin immunoprecipitation-Seq analysis revealed a
cyclin D1-DNA bound form associated with genes that were regulated by estrogen in a cyclin
D1-dependent manner. The cyclin D1-dependent estrogen signaling pathways identified in vivo
were highly enriched for extracellular membrane-associated growth factor receptors (epidermal
growth factor receptor, ErbB3, and EphB3) and their ligands (amphiregulin, encoded by AREG
gene), and matrix metalloproteinase. The AREG protein, a pivotal ligand for epidermal growth
factor receptors to promote cellular proliferation, was induced by cyclin D1 via the AREG pro-
moter. Chromatin immunoprecipitation analysis demonstrated the recruitment of cyclin D1 to the
breast cancer 1 (Brca1)/ER binding site of the Areg gene. Cyclin D1 genetic deletion demon-
strated the in vivo requirement for cyclin D1 in assembling the estrogen-dependent amplified in
breast cancer 1-associated multiprotein complex. The current studies define a requirement for
cyclin D1 in estrogen-dependent signaling modules governing growth factor receptor and ligand
expression in vivo and reveal a noncanonical function of cyclin D1 at ER target gene promoters.
Cyclin D1 mediates the convergence of ER and growth factor signaling at a common cis-element
of growth factor genes. (Molecular Endocrinology 27: 1415–1428, 2013)
The humanCCND1 gene was initially cloned as a com-ponent of a breakpoint rearrangement in parathyroid
adenoma (1). The CCND1 gene is commonly amplified
and/or overexpressed in a variety of humanmalignancies,
including human breast cancer (2). Immunoneutralizing
antibody and antisense experiments demonstrated the
abundance of cyclin D1 is rate limiting in estrogen-in-
duced DNA synthesis and oncogene-induced contact-in-
dependent breast tumor growth in mice (3, 4). Ccnd1
gene knockout mice demonstrated a nonredundant func-
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tion for cyclin D1 in mammary gland development (5–8),
macrophage migration (9), angiogenesis (10), mammary
epithelial cell migration, mitochondrial size and metabo-
lism (11, 12), micro RNA expression (13), and UV radi-
ation sensitivity (14).
The cyclin D1 protein conveys canonical functions as
the regulatory subunit of a holoenzyme that phosphory-
lates target proteins including the pRb protein to inhibit
DNA synthesis, and the nuclear respiratory factor 1
(NRF1) protein to inhibit mitochondrial biogenesis (11,
15, 16). Noncanonical function of cyclin D1 includes as-
sociation with transcription factors and coactivators,
which occur independently of the cyclin D1-associated
kinase activity (17). Association of cyclin D1 with more
than 30 transcription factors (ER, androgen receptor,
and peroxisomal proliferator-activated receptor-) and
tumor suppressors (cyclin D binding myb-like transcrip-
tion factor 1 [DMPF1] and breast cancer 1 [BRCA1]) has
been demonstrated in cultured cells (17). The abundance
of endogenous cyclin D1 determines the recruitment of
transcription factors in the context of local chromatin to
target sequences in ChIP assays (18, 19). Cyclin D1 facil-
itates the recruitment of DNA chromatin-modifying en-
zymes including p300/CREB-binding protein, suppressor
of variegation 3–9 homolog (SUV39H), and Hetero-
chromatin Protein 1 Homolog Alpha (HP1) and cy-
clin D1 is sufficient to alter local histone acetylation
and methylation at target cis-elements. In recent studies
using promoter chromatin immunoprecipitation (ChIP)-
on-ChIP analysis of 12K genes, cyclin D1 was shown to
be recruited to the promoter region of a number of
genes (19).
The clinical observation that cyclin D1 overexpression
is frequently associated with human cancer led to mech-
anistic analysis of cyclin D1 function in estrogen action.
Estrogen induces CCND1 gene expression (20, 21), and
cyclin D1 associates with ER and the steroid receptor
coactivator (SRC)1 (22–24). Estrogen binds ER to co-
ordinate diverse biological functions, with discrete sub-
cellular locations, including the nucleus, cell membrane,
and mitochondria. The ER conducts both nuclear
(genomic) and extranuclear (nongenomic) functions with
dissociable patterns of gene expression (reviewed in Ref.
25). In the nucleus, ER recruits coactivator and core-
pressor complexes in the context of local chromatin. In
addition to local promoter upstream regulatory regions,
ChIP-Seq studies have shown that a substantial propor-
tion of DNA-bound ER occupies downstream promoter
regulatory regions, intragenic regions, and sites distal to
the proximal 1 kb of the transcriptional start site. Non-
genomic actions of 17-estradiol (E2)/ER are conducted
via cytoplasmic membrane and mitochondrial pools of
ER and kinase activation by the membrane-associated
ER (26, 27).
The current studies were conducted to examine at a
high level of resolution the functional significance of cy-
clin D1 in estrogen signaling. First, genome-wide expres-
sion studies conducted on castrated virginCcnd1/mice
treated with E2 identified a molecular signature of cyclin
D1-dependent estrogen signaling that includes 88% of
E2-regulated genes. In the mammary gland, hierarchical
clustering demonstrated these genes include growth fac-
tors, chemokine receptors, and their ligands. Second, we
analyzed genome-wide cyclin D1 ChIP-Seq data, extend-
ing prior ChIP-on-ChIP analysis. These studies demon-
strate that cyclin D1 occupancy is coincident within the
genomic region of 16% of E2-responsive genes. Third, we
show that cyclin D1 signaling converges at a common
DNA response element of the amphiregulin gene (AREG)
promoter that binds ER and BRCA1. Collectively these
studies provide evidence that cyclin D1 participates in
estrogen-regulated gene expression in vivo, governing
growth factor and cytokine signaling.
Materials and Methods
Cell culture
MCF7 and human embryonic kidney 293T cells were ob-
tained from American Type Culture Collection (Manassas, Vir-
ginia) and maintained in DMEM supplemented with 10% fetal
bovine serum, 2 mmol/L glutamine, 100 U/mL penicillin, and
100 mg/mL streptomycin in humidified atmosphere containing
5% CO2 at 37°C. Cells were seeded onto tissue culture dishes
containing phenol red-free DMEM supplemented with 5%
charcoal/dextran-treated fetal bovine serum and cultured for 48
hours before all experimental treatments with hormone.
Ovariectomy and E2 treatment
All aspects of the care and handling of animals used in this
studywere approved by the Institute Animal Care andUseCom-
mittee at Thomas Jefferson University. Genotyping was per-
formed using PCR and primers directed to the murine Ccnd1
gene as previously described (11). For studies of E2 treatment of
mice, animals were castrated and E2 pellets implanted for 7 days
(28). Briefly, female cyclin D1/ and cyclin D1/ mice were
maintained on 12-hour light and 12-hour dark cycles. Mice
were ovariectomized at 5 weeks of age via a dorsal incision
under xylazine (5 mg/kg)-ketamine (50 mg/kg) anesthesia. The
mice were allowed to recuperate for 2 weeks and then were
randomly assigned to either replacement pellets (Innovative Re-
search of America) containing E2 (0.72 mg, 60-day release) or a
pellet containing only the placebo, resulting in 4mice per group.
The mice were then humanely euthanized at day 7 following
pellet implantation. Bromodeoxyuridene (BrDu) was injected 6
hours before the mammary glands of cyclin D1/ and cyclin
D1/mice were excised and analyzed by whole mount to com-
pare the morphology. Mammary glands were also fixed and
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embedded in paraffin. Sections were cut at 5 m and stained for
Ki67 and BrDU. The uterus of mice was also removed and
weighed to validate the efficacy of the ovariectomy and estrogen
pellet implantation.
Plasmids, transfections, and reporter assays
The expression vectors for p3xFLAG-cyclin D1, Rous sar-
coma virus-Renilla luciferase reporter, CMV-Luc, and the cyclin
D1 promoter luciferase reporter constructs were described
previously (29, 30). The ER expression constructions in
p3xFLAG CMV 10 (Sigma-Aldrich) were derived from
pHEGO. The AREG promoter reporter constructs were a gen-
erous gift from Dr J. Parvin and were previously described (31).
The reporter plasmid estrogen response element (ERE)2-TK Luc
contains 2 copies of the vitellogenin A2 estrogen-responsive en-
hancer (11). DNA and small interfering RNA (siRNA) transfec-
tion and luciferase assays were done as previously described (11,
32). Cyclin D1 short hairpin RNA knockdown was conducted
according tomanufacturer’s guidelines (Open Biosystems, Pitts-
burgh, Pennsylvania). Cells were transfected using either cal-
cium phosphate precipitation or Lipofectamine, and the me-
dium was changed after 5 hours. Luciferase activity was
determined after 24 hours. A -galactosidase (-gal) reporter
plasmid was included to control for transfection efficiency. The
fold effect was determined by comparison with the effect of the
empty expression vector cassette.
RNA isolation, quantitative real-time PCR, and
microarray analysis
Total RNA was isolated from mammary gland of transgenic
mice, or MCF7 cells treated with cyclin D1 siRNA or control
siRNAand vehicle or E2 (10 nM) for 24 hours, using Trizol (12).
RNA quality was determined by gel electrophoresis. Probe syn-
thesis and hybridizationwere performed as previously described
(8). For in vivo studies, the labeled probe was used to hybridize
Affymetrix 430 2.0 arrays (Affymetrix, Santa Clara, Califor-
nia). Analysis of the arrays was performed using the R statistics
package and the limma library of the Bioconductor software
package. Arrays were normalized using robust multiarray anal-
ysis, and P value of .05 was applied as statistical criteria for
differential expressed genes (normalized and raw data avail-
able files deposited at Gene Expression Omnibus [GEO];
GSE48884). For in vitro MCF7 studies, labeled probe was used
to hybridize Affymetrix Human Gene 1.0 ST arrays (Af-
fymetrix). Microarray data analysis was conducted using Gene-
Spring software (Agilent Technologies, Palo Alto, California)
(normalized and raw data available files deposited at Gene Ex-
pression Omnibus [GEO]; GSE 48989). The differentially reg-
ulated genes were then grouped using hierarchical clustering
with “complete” agglomeration, and each cluster was further
analyzed based upon the known function of the genes contained
in the cluster. Expression profiles are displayed using TreeView.
Classification and clustering for pathway level analysis em-
ployed DAVID functional annotation (33, 34). Quantitative
real-time PCR was conducted as previously described (35).
ChIP-sequencing and analysis
The cyclin D1 ChIP-Seq has been described pre-
viously (36).
Western blot and Northern blot
The antibodies used in Western blot analysis were to cyclin
D1 (DCS-6), pRb (C-15), ER (H-184), cyclin E (HE-12), CDK
(C-22), pS2 (C-20) (Santa Cruz Biotechnology, Santa Cruz, Cal-
ifornia) and AREG (AF262; R&D Systems, Inc, Minneapolis,
Minnesota). Proteins were visualized by the chemiluminescence
system (Amersham Pharmacia Biotech, Piscataway, New
Jersey).
ELISA
For ELISA, cells were seeded at 80% confluence, and the
growth medium was changed 24 hours later to serum-free me-
dium after samples were washed with PBS. The conditioned
medium was collected 24 hours later, and supernatant was ob-
tained by centrifugation at 2000 rpm for 5 minutes, followed by
filtration through a 0.45-m-pore-size membrane filter. AREG
in the conditioned mediumwas measured using a human AREG
ELISA DuoSet kit (R&D Systems, Inc.) in triplicate, as per the
manufacturer’s recommendations, and normalized by the total
protein levels in the cell lysate of each individual sample. Exper-
iments were conducted at least 3 separate times.
ChIP assay
ChIP analysis was done following a protocol provided by Up-
state Biotechnology (Charlottesville, Virginia). MCF7 cells were
treated with EtOH and E2 for 1 hour. Chromatin solutions were
precipitated overnight at 4°C using 6 g anti-ER (H-184, Santa
Cruz Biotechnology), 4 g anti-Cyclin D1 (HD-11, Santa Cruz
Biotechnology), 4 g anti-FLAG (Santa Cruz Biotechnology), and
4g anti-BRCA1 (C-20, SantaCruz Biotechnology)with rotation.
For a negative control, rabbit IgG and mouse IgG were immuno-
precipitated. ChIP analysis for each immunoprecipitated protein
was conductedon the endogenousAREGpromoter at theBRCA1,
ER, and negative responding sites (35 cycles of PCR). The follow-
ing primers were used: BRCA1, sense 5-TGTCAGGTAC-
TAGCTCCG-3 and antisense 5-GACACACGCCCCGCCT-3;
ERE, sense 5-TTCCTGTCTCCGCTTCATTT-3 and antisense
5-ACTGGTGGAATACTGGCATT-3; Negative, sense 5-
AACTGCTGCACAGCAAAAGG-3 and antisense 5-GAG-
CAAGAACTGGCAGATGG-3.
Gel filtration
Subconfluent MCF7 cells were washed and harvested in PBS
and lysed with a homogenizer in a buffer containing 50 mM
NaCl, 5 mMKCl, 20 mMHEPES (pH 7.5), 1 mM EDTA, 10%
glycerol, a cocktail of protease inhibitors (Roche, Indianapolis,
Indiana), and ligand where appropriate. Samples were centri-
fuged at 27 000  g for 15 minutes at 4°C.
After centrifugation the supernatant was filtered over a
0.22-mpore sizeMILLEX-GP filter (Millipore Corp, Billerica,
Massachusetts) and fractioned on a Superose 6 HR 10/30 gel
filtration column (Pharmacia) preequilibrated with 150 mM
NaCl, 50mM sodium phosphate (pH 7.0), 1mMdithiothreitol,
10 g/mL benzamidine, and 0.7% n-octyl--D-glucopyranoside
(supplemented with ligand where appropriate) at a flow rate of
0.2 mL/min and 400-L fractions were collected. Column cali-
bration was performed under the same conditions with thyro-
globulin (669 kDa), ferritin (440 kDa), catalase (232 kDa), and
aldolase (158 kDa). The void volume of the columnwas 7.0mL.
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Cycloheximide treatment methods
MCF7 cells were maintained in phenol-free DMEM supple-
mented with 5% charcoal-stripped fetal bovine serum at 70%
confluence for 48 hours. Cells were then treated with 20 g/mL
cycloheximide in the presence or absence of E2 (10 nM). After
treatments, Western blot analyses were performed using the
anti-cyclin D1 antibody. GDI serves as protein loading control.
The signal intensity of cyclin D1 was determined by Alpha-
Imager (Alpha Innotech, Santa Clara, California).
Results
Cyclin D1 governs E2-dependent epithelial cell
growth in mammary gland
In order to characterize the biological significance of
cyclin D1 to ER signaling in themammary gland in vivo,
nonpregnant virgin Ccnd1/ mice were examined and
subjected to ovariectomy. After 14 days, when atrophy of
the uterus occurred, estrogen pellets were implanted (Fig-
ure 1A). After a subsequent week of estrogen replace-
ment, animals were euthanized, and the mammary glands
were analyzed. The uteri of Ccnd1/ mice decreased in
size upon ovariectomy but increased partially in the pres-
ence of E2 (Figure 1B). The proliferative effect of estrogen
was partially dependent upon cyclin D1 as previously
described in the uterus (37). Themammary epithelial cells
of female mice undergo massive proliferation in response
to hormone stimulation during pregnancy. However, the
Ccnd1/ mice displayed a severe impairment of mam-
mary gland expansion. TheCcnd1/mice developed the
alveolar lobules, and the density of mammary epithelium
was increased upon E2 treatment (Figure 1C, left panel).
In contrast, the Ccnd1/ failed to respond to E2 treat-
ment in alveolar lobule development (Figure 1C, right
panel).
Mammary epithelial cells were
isolated from the mammary gland,
and the RNA and protein were sub-
jected to analysis. The gene expres-
sion profile confirmed the induction
of genes previously characterized as
estrogen responsive including the
oxytocin receptor (Oxtr), epithelial
growth factor receptor (Egfr), and
growth regulation by estrogen in
breast cancer 1 (Greb1) (38). The
well-characterized E2-responsive pro-
gesterone receptor (PR) gene was in-
duced 8.4-fold in the wild-type mam-
mary gland and approximately
3-fold in theCcnd1/. These find-
ings are consistent with the inter-
pretation of a prior study in which
the PR was induced by E2 in the
Ccnd1/ mammary gland, but il-
lustrate that endogenous cyclin D1
enhances E2-mediated induction of
PR expression (Supplemental Ta-
ble 1 published on The Endocrine
Journals’ Online web site at
http://mend.endojournals.org).
Cyclin D1 regulates genes that
are E2-dependent growth
factors and matrix
metalloproteinases
In the wild-type mammary gland,
608 genes were differentially regu-
lated by E2 with the vast majority
being up-regulated (554 genes) (Fig-
Figure 1. Cyclin D1-Dependent and Independent Function in Estrogen-Regulated Development
in Vivo. A, Schematic depicting experimental procedure for ovariectomy and estrogen pellet
implantation (n  16 female mice). Mice were implanted with an estrogen pellet or placebo
pellet 14 days after ovariectomy. Tissues were harvested at day 21. B, The representative images
of uterus from cyclin D1/ and cyclin D1/ mice with or without estrogen treatment. Graph
depicts uterus weights as a percentage of body weight in cyclin D1/ and cyclin D1/ mice
with or without estrogen treatment. C, Mouse mammary gland whole mounts stained with
Carmine dye.
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ure 2A and Supplemental Table 1). In contrast, only 134
genes were differentially regulated by E2 in the Ccnd1
/
mice. These results suggest that the vast majority (537
genes; 88%) of E2-regulated gene expression is dependent
upon endogenous cyclin D1 in vivo.
Pathway analysis (PANTHER; Biological Process) was
conducted using DAVID bioinformatics resource to de-
termine the gene signaling modules induced by E2 in a
cyclin D1-dependent manner. These analyses demon-
strated the estrogen-mediated gene signaling pathways
including cellular adhesion, migration, and extracellular
matrix (ECM)-linked receptor protein signaling (for ease
of comparison, the mean fold induction by E2 of
Ccnd1/ vs Ccnd1/ is shown as a chart to the right of
Figure 2. Genome-Wide Profiling of Cyclin D1-Dependent Estrogen-Regulated Genes in Vivo. A, Venn diagram displays the number of genes
that were differentially regulated by estrogen in cyclin D1/ mouse mammary glands compared with cyclin D1/ mouse mammary glands. The
directionality of change is depicted by up and down arrows. B, Cyclin D1-dependent estrogen-regulated genes were grouped by hierarchical
clustering via complete linkage (Cluster 3.0) and visually depicted using Treeview (left). The up-regulated genes are in red and down-regulated
genes are in green (P  .05). Chart to the right of heat map depicts Log2 fold change of E2-induced and -repressed genes comparing cyclin D1
/
with cyclin D1/ mouse mammary glands. C–E, DAVID analysis was used to classify the pathways differentially regulated by cyclin D1 in E2-
treated mice. Pathways depicted represent member genes from microarray analysis of estrogen-treated cyclin D1/ mouse mammary glands vs
cyclin D1/ mouse mammary glands, growth factors (C), growth factor receptors (D), and peptidases (E). V, vehicle; Veh., vehicle.
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the heat map) (Figure 2B and Supplemental Figure 1).
Examination of individual genes within these pathways
identified enrichment for growth factor and cytokine re-
ceptors and their ligands (Figure 2, C–E). The individual
genes were tabulated as growth factor receptors (ie, Egfr,
Erbb3, and Pdgfr), growth factor ligands (ie, Areg), mem-
bers of protease-regulatory protein families (a disintegrin
and metalloproteinase with thrombospondin motif
(Adamts)), tissue inhibitor of metalloprotease and matrix
metalloprotease (MMP) families.
Examination of the individual genes induced by E2 in a
cyclin D1-dependent manner identified a group of genes
well known to be induced by estrogen, which include the
progesterone receptor (Pgr) gene, the estrogen-responsive
gene (c-jun), and a group of several other genes induced
by DNA damage repair (Perp, TP53 apoptosis effector),
TNF-induced protein 6, dual specificity phosphatase 4,
TNF receptors family member 12A, stanniocalcin 2, in-
terferon-induced protein with tetratricopeptide repeats 1,
heat shock protein 1A, nucleoredoxin, and immediate
early response 3 (Supplemental Figure 2). These studies
suggest that endogenous cyclin D1 participates in estro-
gen-dependent gene expression including estrogen-re-
sponsive genes induced by DNA damage-mediated
signaling.
Gene ontology (GO) terms used to define genes in-
duced by E2 via cyclin D1 encompassed genes involved in
growth factor signaling, growth factor receptors and li-
gands, and extracellular peptidases (Figure 2, C—E, and
Supplemental Figure 1). Areg, a ligand for the Egfr re-
quired for epithelial cell proliferation, terminal end bud
formation, and ductal elongation in the mouse mammary
gland and a known target of ER action (Ref. 39; re-
viewed in Ref. 40), was up-regulated 17-fold. Addition-
ally, Egfr, the receptor for Areg, was up-regulated 4-fold
by E2 in the Ccnd1
/ but not in the Ccnd1/ mouse
mammary gland.
The finding that most E2-dependent genes required cy-
clin D1 for their expression in vivo led us to examine
further the requirement for cyclin D1 in E2 signaling in
human breast cancer cells. In order to characterize the
role of cyclin D1 in estrogen signaling in MCF7 cells,
experiments were first performed to determine cyclin D1
responsiveness to E2 treatment. The effect of E2 on cyclin
D1mRNA stability has been explored previously (41). E2
induced the expression of cyclin D1 at approximately 2
hours with the sequential phosphorylation of Rb (Supple-
mental Figure 3). E2 addition toMCF7 cells did not affect
cdk4 abundance, but, consistent with prior observations
(42), was associated with a modest reduction in the rela-
tive abundance of ER (Supplemental Figure 3A). Cyclin
D1 mRNA abundance was induced within 30 minutes
(Supplemental Figure 3B), and cyclin D1 promoter activ-
ity was induced, consistent with our prior studies (21),
demonstrating the cyclin D1 promoter is a transcriptional
target of the ER (Supplemental Figure 3C). These find-
ings are also consistent with prior ChIP analysis of the
cyclin D1 gene that identified an ER binding-enhanced
element within the proximal 60 bp of the transcrip-
tional start site (43). E2-dependent induction of cyclin
D1 was monitored after the inhibition of transcription
through the use of cycloheximide (Supplemental Figure
3, D and E). Cyclin D1 half-life was not affected by the
addition of E2.
Next we conducted microarray analysis on E2-stimu-
latedMCF7 cells treatedwith cyclinD1 siRNA in order to
compare the genes regulated by cyclin D1 in mammary
gland to those regulated by cyclin D1 in transformed ep-
ithelial cells. Hormone-deprivedMCF7 cells were treated
with cyclin D1 siRNA or control siRNA and stimulated
with E2 or vehicle. In the control siRNA-treated MCF7
cells 2902 genes were differentially regulated by E2 (Sup-
plemental Figure 4, A and B, and Supplemental Table 3).
In contrast, only 244 genes were differentially regulated
by E2 in cyclin D1 siRNA-treated MCF7 cells. Pathway
analysis on the 2744 cyclin D1-dependent E2 -regulated
genes showed significant overlap to those pathways pre-
viously identified as being mediated by ER receptor sig-
naling including, cell cycle, mitosis, andDNA repair (Sup-
plemental Figure 4C). These results suggest that the vast
majority of E2-regulated gene expression is dependent
upon endogenous cyclin D1 in vivo and in vitro. How-
ever, we observe a substantial difference in the genes and
pathways that are regulated by cyclin D1 in transformed
epithelial cells compared with the whole mammary gland
(Supplemental Figure 4D). The difference may be due to
distinguishable roles for cyclin D1 in estrogen-stimulated
function in transformed epithelial cells vs normal mam-
mary gland.
Whole-genome analysis of cyclin D1 binding in
chromatin shows a high incidence of occupancy at
genes that are regulated by E2
A substantial amount of evidence that directly impli-
cates cyclin D1 in regulating transcription through bind-
ing DNA sequences within local chromatin of target gene
promoters has accumulated over the past decade (29, 44–
46). We were interested in comparing genes regulated by
E2 in vivo to those occupied by cyclin D1. Recent studies
using ChIP-on-ChIP interrogated approximately 12 000
gene proximal promoter-regulatory regions. Because
ER-responsive elements may be located at distal sites,
we extended the analysis to include the additional ap-
proximately 99% of the genome using ChIP-Seq technol-
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ogy, which provides an unbiased whole-genome ap-
proach. We analyzed ChIP-Seq data derived from mouse
embryonic fibroblasts derived from Ccnd1/ mice res-
cued with an expression vector encoding FLAG-cyclin D1
and immunoprecipitated cyclin D1-bound chromatin
with an anti-FLAG antibody (36). The anti-FLAG IP ap-
proachwas used due to the technical challenges of ChIP to
endogenousmurine cyclin D1 (19, 44, 45). Cyclin D1was
associated with genomic intervals that neighbored ap-
proximately 2800 genes (10 000 to 10 000 of the
transcriptional start and end sites, respectively) (36). We
then compared the genes occupied by cyclin D1 at the
DNA level with those regulated by E2 in vivo. Approxi-
mately 16% of the E2-regulated genes bound cyclin D1 in
ChIP-Seq (Figure 3A and Supplemental Table 2).
The vast majority (88%) of the E2-regulated genes in
the mammary gland in vivo were regulated by E2 in a
cyclin D1-dependent manner (Figure 3B and Supplemen-
tal Table 1). The cyclin D1 occupancy of the genes regu-
lated by E2 in a cyclin D1-dependent manner was distrib-
uted upstream of the transcription start site (27 intervals),
downstream of the gene (22 intervals) or intragenic (56
intervals) (Figure 3C). Representative tag-density profiles
of genes bound by cyclin D1 are depicted in Figure 3D,
including Epgn (epithelial mitogen homolog), Eps8 (epi-
thelial growth factor receptor pathway substrate 8), and
Mmp2 (mitoticmetallopeptidase 2). A full list of the genes
is provided in Supplemental Table 2. The results are con-
sistent with a role for cyclin D1 in an ER transcriptional
program that governs growth factor signaling and pepti-
dases involved in ECM degradation.
Cyclin D1 and BRCA1 converge to regulate AREG
expression
AREG, a well-known ER target gene (39), was in-
duced approximately 17-fold by E2 in the microarray
analysis of the Ccnd1/ mammary gland but not in the
Ccnd1/ mammary gland (Supplemental Table 1). In
order to determine the role of cyclin D1 in E2-regulated
AREG expression, cyclin D1 mRNA was knocked down
in MCF7 human breast cancer cells
using 3 distinct cyclin D1-targeted
siRNA (Figure 4A). AREG expres-
sion was measured by Western blot,
ELISA, and quantitative RT-PCR
(Figure 4, B–D). In MCF7 cells with
cyclin D1 siRNA knockdown, we
observed a reduction in E2-induced
AREG mRNA levels determined by
RT-PCR analysis (Figure 4B), a re-
duction in E2-induced AREG abun-
dance by Western blotting (Figure
4C), and a reduction in E2-induced
protein by ELISA (Figure 4D).
AREG promoter reporter assays
were conducted to determine
whether cyclin D1 directly induced
AREG transcription. Our previous
studies had shown that cyclin D1
regulated estrogen-dependent gene
expression via a cyclin D1/BRCA1
complex (29). We therefore investi-
gated the possibility that cyclin D1-
ER signaling and BRCA1 signaling
may converge on common DNA cis-
elements of growth factor genes. We
deployed an AREG promoter frag-
ment known to include the BRCA1
repression element (31). Cyclin D1
expression induced the transcrip-
tional activity of the AREG pro-
moter (Figure 4E). Using a series of
Figure 3. Genes Regulated by E2 in Vivo Are Bound by Cyclin D1 by ChIP-Seq. A, Comparison
of genes occupied by cyclin D1 in ChIP-Seq to those regulated by E2 in cyclin D1
/ mouse
mammary gland and (B) those E2-responsive genes that are regulated in a cyclin D1-dependant
manner. C, Location of and (D) representative tag density profiles for, cyclin D1-occupied genes
that are regulated by E2. Vertical axis shows average peak height and horizontal axis depicts
chromosomal location of cyclin D1-associated interval sequence. TSS, transcription start site.
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AREG promoter reporter constructs, we identified a re-
gion of theAREG gene promoter that was responsible for
induction by cyclin D1 between 202 and 182 (Figure
4, E and F). This region was previously identified as the
BRCA1-repression element of the AREG promoter (31).
The BRCA1 response element is predicted to also occur in
the murine AREG promoter with high confidence (87%
and 94%) at a similar location (Figure 4G) using a tran-
scription factor prediction software (JASPAR).
To confirm whether BRCA1 and/or the ER bound to
the AREG promoter region in local chromatin, ChIP as-
sayswere conducted inMCF7 cells. The3322 to3169
region was used as a form of nega-
tive control. BRCA1 was recruited
to both the previously defined ERE
of the AREG promoter between
912 and763, and also bound the
202 to182 region defined as the
BRCA1 response elements. ERwas
identified by ChIP at both the ERE
and BRCA1 response elements but
was not identified at the negative
control 3322 to 3169 site (Fig-
ure 5A). As a form of positive con-
trol for ER, the pS2 gene was used.
ER was recruited to the AREG
gene promoter independent of li-
gand presence although the ER oc-
cupancy of pS2 gene promoter was
entirely dependent on E2 (Figure
5B). MCF7 cells were transduced
with a retrovirus encoding cyclin
D1; immunoprecipitation-Western
blot detected the FLAG epitope of
the cyclin D1 protein (Figure 5, C
and D). Cyclin D1, detected by anti-
FLAG antibody, was recruited to the
AREG promoter with increased re-
cruitment in the presence of E2 by
FLAG-ChIP (Figure 5D). In order to
determine whether the AREG gene
served as a direct target induced by
cyclin D1, ChIP assays were per-
formed using antibodies directed to
either FLAG-tagged cyclin D1 or to
endogenous cyclin D1. Antibody di-
rected to endogenous cyclin D1 in
control MCF7 cells was used to
identify cyclin D1 at the AREG pro-
moter (Figure 5E). E2 treatment en-
hanced recruitment of cyclin D1 to
the AREG promoter202 to182
region. E2 treatment reduced BRCA1 and ER occupancy
(Figure 5E). Together, these studies demonstrate E2 treat-
ment results in increased cyclin D1 and reduced BRCA1
occupancy at the AREG promoter.
Previous studies demonstrated that immunoprecipita-
tion of BRCA1 coprecipitates cyclin D1 (29, 47). In view
of the finding that cyclin D1 regulated the AREG pro-
moter via the BRCA1-binding site, we sought to define
minimal elements of interaction between cyclin D1 and
BRCA1. Previous studies had shown full-length cyclin D1
bound BRCA1 in immunoprecipitation-Western blot and
colocalized by confocal microscopy in a subset of nuclear
Figure 4. ER Induces AREG Gene Expression in a Cyclin D1-Dependent Manner. A and B,
MCF7 cells were transfected with siRNAs targeting cyclin D1 and treated with vehicle or E2 (10
8
M) for 24 hours. CCND1 and AREG mRNA abundance was determined by quantitative RT-PCR.
C, Western blot was performed to determine the cellular levels of AREG expression in cyclin D1
knockdown cells compared with scramble siRNA control. -tubulin was included as loading
control for protein abundance. D, The concentration of AREG in cell culture medium was
measured by ELISA. Concentration of AREG in the conditioned media was normalized to total
protein. Data are mean  SEM. E, AREG promoter luciferase reporter plasmids were transfected
into MCF7 cells with a cyclin D1 expression vector. Relative luciferase activity is shown as mean 
SEM normalized to -galactosidase activity of a cotransfected vector and as (F) fold-induction by
cyclin D1. G, Promoter sequence alignment of mouse and human amphiregulin promoter.
Homologous nucleotides (:) and regions of discontinuity () are indicated. Predicted BRCA1 sites
are highlighted for human ( strand), and mouse (2 sites on  strand) with predicted confidence
values of 86%, 87%, and 94% respectively. Ctrl., control.
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dots (29). To define the minimal interaction domains,
glutathione-S-transferase (GST) pull-down experiments
were conducted with GST-cyclin D1 and BRCA1 protein
produced by in vitro translation (Figure 5, F and G). The
in vitro translated BRCA1 regions between 1–302, 34–
302 or 67–300 were sufficient for binding to GST-cyclin
D1 (Figure 5H). The GST-cyclin D1 fragment used in
pull-down analysis with BRCA1 demonstrated that the
BRCA1 region between 1–302 and from 1–100 was able
to bind cyclin D1 (Figure 5, H and I).
E2 increases the abundance of
cyclin D1/amplified in breast
cancer 1 (AIB1) lower molecular
weight coeluting fractions
ER is known to reside in distinct
multiprotein complexes that can be
assessed through Superose 6 frac-
tionation of cell lysates. We con-
ducted experiments in order to ad-
dress whether cyclin D1 may
contribute to the formation of the
ERmultiprotein complexes. To do
so, we first examined MCF7 cells in
response to E2. E2 treatment resulted
in the increased relative abundance
of ER within a high molecular
weight complex of approximately 4
mDa (named as HMW complex
[HMC]) (Figure 6A). Cyclin D1,
which binds ER in vitro, coeluted
in several fractions; in the HMC
with BRCA1 and ER (Figure 6A,
fractions 19–22), and cyclin D1 was
also observed in 670 kDa (LMW
complex [LMC]) complexes (Figure
6A, fractions 31–36). Cdk4 eluted
primarily in the 440 kDa complexes
(fractions 37–40).
In order to characterize further
the proteins within the 670 kDa
LMC complexes, Western blot anal-
ysis was conducted on the Superose
6 fractions. We examined the effect
of E2 on the distribution of several
ER coactivator known to bind cy-
clin D1, including SRC-1, AIB1, and
P/CAF. E2 treatment increased
abundance of the ER coactivator
AIB1 in the low molecular weight
(LMW) fraction of MCF7 cells,
with no significant change for
SRC1 and P/CAF (Figure 6B). In
order to determine whether the coeluting fraction of
ER and AIB1 were physically associated, and to de-
termine whether E2 increases the amount of AIB1
bound to ER as previously shown, immune-precipita-
tion Western blotting was conducted (Figure 6C). The
addition of E2 increased the relative abundance of AIB1
associated with ER. A reduction in cyclin D1 abun-
dance by short hairpin RNA reduced the amount of
cyclin D1 associated with ER but did not abolish AIB1
binding.
Figure 5. Cyclin D1 Is Recruited to a BRCA1 Binding Site. A, ChIP assay in MCF7 cells treated
with E2 (10 nM) for ER at the AREG gene promoter. B. The pS2 gene was included as a positive
control. C, Western blot shows FLAG-cyclin D1 expression in transduced MCF7 cells. D, ChIP
assay to determine cyclin D1 occupancy at the AREG gene promoter. Using either MCF7 cells
transduced with FLAG-cyclin D1 or (E) MCF7 cells ChIP analysis with antibodies directed to
endogenous cyclin D1, BRCA1 or ER (E2 10 nM 24 hours). F and G, GST pulldown was
performed to determine the minimal region of BRCA1 required for cyclin D1 binding. H and I,
GST-cyclin D1 or mutants were incubated with in vitro translated BRCA1. The N terminus (1–100
amino acids) of cyclin D1 was required for BRCA1 binding. IB, immunoblot; IP,
immunoprecipitation; IVT, in vitro translation.
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Cyclin D1 facilitates loading of the ER coactivator
LMW complex (LMC) in vivo
To determine whether cyclin D1 was required for the
formation of the 670 kDa LMC complex in epithelial cells
expressing BRCA1 and ER in vivo, analysis was per-
formed on tissues from female Ccnd1/mice with com-
parison to age and gender-matched littermate Ccnd1/
control animals. The mammary gland of the Ccnd1/
mice is unsuitable for analysis because the organ develops
aberrantly. In contrast, Ccnd1/ liver development is
normal, the liver expresses BRCA1, and a substantial lit-
erature on ER-regulated gene expression is documented
for this organ. Superose 6 fraction-
ation demonstrated the presence of
the 670 kDa LMC complex contain-
ing ER and cyclin D1 in the wild-
type mice liver extracts (Figure 7A).
In contrast, the ER fromCcnd1/
cells eluted in the  4 mDa HMC
complex (Figure 7B). These studies
demonstrate that cyclin D1 is re-
quired for the formation of the 670
kDa LMC ER complex in vivo.
Discussion
Cyclin D1 is known to regulate gene
expression in cultured cells through
several different mechanisms (48),
indirectly through phosphorylation
of pRb and the induction of E2F-
dependent gene expression (3) and
directly through binding target
genes in the context of local chroma-
tin (29, 44, 45). The current studies
extend these findings by demon-
strating the importance of endoge-
nous cyclin D1 in estrogen-depen-
dent gene expression in vivo. E2-
regulated gene expression (88%
[532/608]) was compromised in the
mammary gland of Ccnd1/ mice.
Cyclin D1 was required for estro-
gen-dependent expression of a sub-
set of genes. These genes were in-
volved in growth factor and
cytokine signaling. We demon-
strated two mechanisms by which
cyclin D1 augments ER signaling.
First, we demonstrated the require-
ment for cyclin D1 in the formation
of an AIB1/ER LMW coactivator
complex in vivo using Ccnd1/ mice tissue. Second, ge-
nome-wide ChIP-Seq analysis identified cyclin D1 occu-
pancy at 16%of cyclin D1-dependent E2-regulated genes.
Further ChIP analysis demonstrated that cyclin D1 is re-
cruited to the BRCA1-binding site of theAREG promoter
upon E2 treatment, associatedwith reduced occupancy by
BRCA1. E2 regulates gene expression through canonical
and noncanonical binding sites. The finding that cyclin
D1 was identified by ChIP-Seq in ER-negative cells at
16% of the genes regulated by E2 in the mammary gland,
suggests that cyclin D1 occupies noncanonical as well as
Figure 6. E2 Induces Cyclin D1 Distribution within a LMW Complex with AIB1. A,. Western
blot analysis of Superose 6 chromatography from asynchronously cycling MCF7 cell lysates using
antibodies as indicated to the left of the figure. The molecular weight of the fractions is indicated
at the bottom of the figure. Cells were treated with () E2 (10
8 M). The coeluting fractions  4
mDa (HMC) and 670 kDa (LMC) are indicated by the boxes. B, Western blot analysis of MCF7 cell
extracts after Superose 6 chromatographic fractionation. The antibodies are as indicated. Extracts
were treated with E2 (10
8M) for 30 minutes. Molecular weight markers are shown below panel
B, indicating the HMC (4 MDa) or LMC (670 kDa). C, Hormone-deprived MCF7 cells infected
with shCCND1 or shControl were treated for 1 hour with 10 nM E2 or vehicle control; ER was
immunoprecipitated followed by Western blotting for AIB1, cyclin D1, and ER. IP,
immunoprecipitation; V, vehicle.
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canonical EREs. However, the chromatin and epigenetic
landscapes in mouse embryonic fibroblasts compared
with transformed epithelial cells are likely quite different
and therefore the cyclin D1-associated transcription fac-
tors are likely different. Future studies conducted to sur-
vey cyclinD1 in the context of chromatin under hormonal
activation in epithelial cells would add to our understand-
ing of this proto-oncogene.
Prior studies demonstrated that progesterone receptor
(PR) expression is induced in response to an injection of
E2 in Ccnd1
/ mice (49). In contrast, recent studies of
mouse mammary tumor virus-cyclin D1 transgenic mice
showed enhanced PR expression upon E2 treatment. The
PR gene was also induced by cyclin D1 expression in
transient expression experiments (50). The current stud-
ies extend these prior observations by carefully quantify-
ing the gene expression induced by E2 in a cyclin D1-
dependent manner and by conducting a genome-wide
interrogation of candidate target genes. Herein, the in-
duction of PR expression by E2 was reduced 4-fold in the
Ccnd1/ mammary gland in vivo; this suggests that cy-
clin D1 plays a role in augmenting, but is not absolutely
required for, E2 signaling to the PR gene.
Growth factors induced by E2 in a
cyclin D1-dependent manner in-
clude Areg, which is known to play a
critical role in mammary gland de-
velopment. AREG is a ligand for the
epidermal growth factor receptor
(EGFR) and is the most abundant
growth factor in the pubertal mam-
mary gland (40). The Areg/ mice
demonstrated that Areg is essential
for breast ductal elongation and es-
trogen-induced terminal end bud de-
velopment, which resembles that of
the Esr1 and Egfr knockout mice
(39). In the current studies, the in-
duction of Areg expression by E2
was abrogated in the Ccnd1/
mammary gland. Endogenous cyclin
D1 contributed to a 17-fold increase
in E2-mediated Areg expression.
Breast epithelial cell proliferation,
migration, and invasion are en-
hanced by AREG. There is a corre-
lation between AREG expression
and breast cancer aggressiveness in
cells, and the inhibition of AREG ex-
pression reduces tumor formation in
vivo (51). The 17-fold induction of
Areg in the murine mammary gland
by E2 may have been enhanced through heterotypic sig-
nals. In human MCF7 cells, however, siRNA-mediated
reduction of cyclin D1 reduced E2-induced AREG protein
levels, suggesting a cell autonomous effect of cyclin D1 to
enhance AREG abundance.
Prior studies using ChIP assays and bioinformatics
analysis of ChIP-Seq data demonstrated cyclin D1 occu-
pancy at endogenous EREs in ER-positive breast cancer
cell lines and ER-negative fibroblasts (29, 36). In these
prior studies conducted in ER expressing cells, E2 treat-
ment (1 hour) enhanced cyclin D1 recruitment in chro-
matin to canonical EREs. Herein, expression of cyclin D1
enhanced AREG promoter activity via promoter elements
202 to182. This element was previously identified as
the AREG promoter element repressed by BRCA1 (31)
and is conserved with the murine Areg promoter. Herein
we have shown that this region of the AREG promoter
binds BRCA1 and ER. These findings are consistent
with prior studies in which cyclin D1 antagonized
BRCA1 activity and cyclin D1 was shown to displace
BRCA1 occupancy at endogenous target genes in ChIP
assays, potentially via phosphorylation of BRCA1 at
Ser632 (29, 47).
Figure 7. ER Recruitment to the LMW Complex Requires Cyclin D1. A, Western blot analysis
of superose 6 chromatographic fractions from female cyclin D1/ or cyclin D1/ mice cell
lysates (liver) using antibodies as indicated to the left of the figure. The molecular weight markers
are shown below. B, The relative abundance of ER in the HMC or LMC (670 kDa) is shown
graphically indicating increased ER in the HMC in cyclin D1/ mice. C, Schematic presentation
of cyclin D1 regulation of ER activation proposes a model in which cyclin D1 participates in ER
signaling by binding to BRCA1 and in the presence of E2 facilitates an LMC that includes ER and
AIB1. Cyclin D1 binding to BRCA1 antagonized BRCA1 action, including BRCA1 repression of
Areg expression.
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Knockdown of cyclin D1 in MCF7 cells reduced the
E2-induced secretion ofmature AREG into the cell culture
medium. This finding suggests that cyclin D1 may func-
tion to promote posttranslational modification of AREG.
In human breast carcinomas, AREGwas overexpressed in
half of the specimens whereas staining for AREG in nor-
mal mammary gland is only weakly positive (52). The
metalloprotease, TNF-converting enzyme (ADAM17),
enhances the shedding of AREG, which is also enhanced
by TGF, HB-EGF, and other ADAM proteins (reviewed
in Ref. 53). In the current studies, endogenous cyclin D1
enhanced the abundance of ADAM17, raising the possi-
bility that cyclin D1 may induce AREG maturation/acti-
vation through up-regulating ADAM17 expression.
Herein, cyclin D1 enhanced estrogen-dependent ex-
pression of several peptidases, in vivo, including
Adamts1. In breast cancer cells in culture, estrogen in-
duces patterns of gene expression governing cellular pro-
liferation, migration, and invasion (54). In the current
studies of MCF7 cells, distinct gene expression profiles
were induced by E2 compared with the genes induced in
the mammary gland in vivo; however, as with the in vivo
setting, a substantial proportion of E2-responsive genes
were dependent upon endogenous cyclinD1. The findings
are consistent with prior studies in which distinct gene
profiles were induced by progesterone in normal vs ma-
lignant breast cancer cells (55). The invasion of cells re-
quires proteolytic cleavage of the ECM. The metallopro-
teinases convey critical functions in cellular migration
(24, 49). The disintegrin and metalloproteinase with
thrombospondinmotif (ADAMTS1) protein bind and de-
grade the ECM, including aggrecan and versican, to
thereby promote pulmonary (56) and bone metastasis
(57). Elevated ADAMSTS1 is enriched in metastatic
breast cancer (58), and ADAMTS1 promotes primary
metastasis of TA3 mammary carcinoma (59). Higher lev-
els of ADAMTS1 are seen in the primary tumors of pa-
tients who subsequently develop bone metastases (57).
The finding that endogenous cyclin D1 activates matrix
peptidases, which in turn can contribute to growth factor
signaling, is consistent with several recent studies. Cyclin
D1 induced plasminogen activator inhibitor and u-plas-
minogen activator activity (60), MMP, and Adamts pep-
tidases (Adamts1, Adamts4, Adamts15, Adamts19). The
Notch receptor is activated and cleaved by TNF-con-
verting enzyme (ADAM17). Cyclin D1 was previously
shown to induce Notch receptor activity (61). Notch in-
tracellular domain abundance correlates with cyclin D1
abundance in a variety of cell types and cyclin D1 induced
notch intracellular domain and enhanced Notch activity
(61). The importance of cyclin D1-dependent induction
ofmatrix peptidases in governing tumor progressionwar-
rants further analysis.
These studies also extend prior findings that cyclin D1
antagonizes BRCA1 in cultured cells first by showing cy-
clinD1 induces AREGvia the BRCA1 repression element,
second by showing the abundance of cyclin D1 is a critical
determinant of ER containing coactivator or corepres-
sor complexes which coeluted with BRCA1, and third by
demonstrating that the N-terminal residues 1–101 of
BRCA1 are required for interaction with cyclin D1. The
finding that BRCA1 amino acids 1–100 bind cyclin D1
supports our prior studies at high resolution in which
cyclin D1 associated with BRCA1 via the N-terminal re-
gion amino acids 1–500 (29, 47).
Previous studies demonstrated that cyclin D1 interacts
with ER in a ligand-independent manner, and cyclin D1
is known to participate in the formation of an ER co-
activator complex in vitro (22–24). The Superose 6 frac-
tionation studies conducted of murine tissues herein are
consistent with the prior findings in tissue culture (22)
that cyclin D1 functions as a chaperone protein to facili-
tate the formation of multiprotein complexes including
AIB1 in vivo. In the current studies using mice tissue, the
relative abundance of ERwithin the LMCwas increased
in the presence of cyclin D1 (Figure 7C). Deletion of the
Ccnd1/ gene resulted in a relative increase in the abun-
dance of ER in theHMC. Together these studies provide
in vivo support for a model in which cyclin D1 facilitates
the formation of the ER-coactivator complex and dis-
places the ER corepressor BRCA1. This priming of the
ER coactivator and corepressor complexes serves to co-
ordinate expression of a substantial proportion of ER-
regulated genes in vivo and in tissue culture.
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